Skip to main navigation

Investor Relations

Investors & Media
Contact Us
Careers

Overview
News / Events
Company
Financial
Stock
SEC Filings
Governance

Overview
News / Events
Company
Financial
Stock
SEC Filings
Governance

Press Releases

Year

Jul 28, 2021

BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021

Jul 19, 2021

BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Jun 23, 2021

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 22, 2021

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

Jun 18, 2021

BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021

May 26, 2021

BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

May 19, 2021

BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

May 11, 2021

BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference

May 10, 2021

BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

May 04, 2021

BioXcel Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 11 - 20 of 35

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Pipeline
Our Science
Patients & Advocacy

Investors & Media
Contact Us
Careers

Copyright © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap